Boehringer Ingelheim appoints Abdallah Hamed as GM and Head of Human Pharma

Boehringer Ingelheim, a global biopharmaceutical company, has appointed Abdallah Hamed as General Manager and Head of Human Pharma for the Saudi Arabia, Gulf, and East Africa (SAGEA) region, effective October 1, 2024.

In his new role, Abdallah brings over two decades of leadership experience and will focus on advancing Boehringer Ingelheim’s strategic priorities, fostering innovation, and driving market growth across key healthcare areas. Before his appointment, he held key roles at Merck, most recently as Managing Director for KSA.

Abdallah holds a BSc degree in Pharmacy from Applied Science University in Jordan and completed an executive Global Healthcare Leadership Programme at Harvard University. And brings strong competencies to bolster company's presence across the region.

Welcoming Abdallah to the leadership team, Derek O’Leary, Regional Managing Director for India, Middle East, Turkey, and Africa (IMETA) at Boehringer Ingelheim, said, “We are delighted to welcome Abdallah to lead our operations in the SAGEA region. His wealth of experience and dedication to advancing healthcare will play a crucial role in strengthening Boehringer Ingelheim’s presence and impact across the region. I am confident that, under his leadership, we will continue to innovate to transform lives for generations, deliver value to patients, and build strong partnerships with healthcare stakeholders.”

You may also like:

• Why employees need both AI and green skills
• India-UAE partnership: A vision for 2030 and a new global order
• 83% of UAE boards dedicating time for discussions around AI and workforce engagement
• UAE mandates women representation on Private Company Boards

Abdallah added, “Over the past two decades, I have witnessed the incredible transformation of the regional pharmaceutical industry, driven by changing healthcare needs, growing demand for innovative and personalised treatments, breakthroughs in medical technology, and an increased emphasis on patient-centric care. As this dynamic market continues to advance, I am excited to help shape its future by leveraging Boehringer Ingelheim's global expertise and resources. By building on our existing relationships, fostering new collaborations, driving innovation, and addressing local healthcare challenges, we aim to continue delivering sustainable healthcare solutions that make a meaningful impact on human and animal lives.”